Plant will be CDMO’s first standalone GMP and vaccine development manufacturing site in the country
WuXi Vaccines, a contract development and manufacturing organization (CDMO) and subsidiary of WuXi Biologics, announced that it has entered into an agreement with Harbour BioMed under which Harbour BioMed's manufacturing facility in Suzhou, China will be transferred to the CDMO.
The 91,500 square-foot facility features multiple 250L, 500L and 1000L single-use bioreactors, along with sterile drug-product manufacturing lines. The plant will be renovated to provide vaccine development and good manufacturing practice (GMP) manufacturing services for its global partners. It will also be WuXi Vaccines' first standalone vaccine development and GMP manufacturing site in China.
"We are very pleased to enter into this agreement with Harbour BioMed,” says Jian Dong, CEO of WuXi Vaccines. “This is a win-win agreement for both of our companies. … We are committed to advancing the accessibility and affordability of high-quality vaccines, with integrated technology platforms that enable our global partners to enhance the well-being of people worldwide."
Read more about the CDMO’s new facility here.